⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16392571 | 1.00 | — | — | |
| Methane SCHEMBL20815722 | 0.97 | — | — | |
| SCHEMBL11955199 | 0.86 | THRB (0.39) | — | |
| SCHEMBL21982063 | 0.84 | — | — | |
| SCHEMBL24133914 | 0.84 | THRB (0.43) | — | |
| SCHEMBL24517614 | 0.84 | THRB (0.43) | — | |
| SCHEMBL21776329 | 0.84 | — | — | |
| SCHEMBL22026383 | 0.84 | THRB (0.43) | — | |
| SCHEMBL13317628 | 0.84 | THRB (0.43) | — | |
| SCHEMBL23467851 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0473387-A2 | Anti-fungal triazole derivatives, their preparation and uses | Sankyo Company Limited (JP) | 1992-03-04 | — | — | EP | claimed |
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-11-21 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| CN-105884981-B | A kind of low-shrinkage light-cured resin for 3D printing | 湖南华曙高科技有限责任公司 | 2019-01-18 | — | — | CN | disclosed |
| US-10035889-B2 | Optical film | MITSUI CHEMICALS, INC. (JP) | 2018-07-31 | — | — | US | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20160032063-A1 | Optical Film | KEIO UNIVERSITY (JP) | 2016-02-04 | — | — | US | disclosed |
| US-5489606-A | FUNGICIDES, HUMAN, VETERNARY MEDICINE | SANKYO COMPANY, LIMITED (JP) | 1996-02-06 | — | — | US | disclosed |
| US-5393769-A | Thio-, sulfinyl- or sulfonyl-substituted | SANKYO COMPANY, LIMITED (JP) | 1995-02-28 | — | — | US | disclosed |
| EP-0629192-A1 | HERBICIDALLY ACTIVE PYRIMIDINYL AND TRIAZINYL COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994010156-A1 | HERBICIDALLY ACTIVE PYRIMIDINYL AND TRIAZINYL COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-05-11 | — | — | WO | disclosed |